Group items tagged

The Royal Pharmaceutical Society (RPS) and National Pharmacy Association (NPA) have both urged the new health secretary Steve Barclay to back the 'pharmacy first' approach in England as mentioned by his predecessor on numerous occasions. "Sajid Javid recognised the vital role of community pharmacy and the potential of a 'Pharmacy First' to support patient access to care. I would urge the new Health Secretary to see this through to completion," said chair of RPS in England Thorrun Govind. Thorrun hopes the new health secretary will engage with pharmacy leaders about how we can make the most of our health and care workforce to support the NHS recovery, including reducing health inequalities, managing the growing cost of long-term conditions, and utilising the enhanced skills of Pharmacist Independent Prescribers. Commenting on the new appointment, she said: "This is a crucial time for the future of health and care - with continued pressures on teams, changes to NHS structures and organisations, and the need for long-term investment in the workforce. "With a 'refresh' of the NHS Long-Term Plan and the Government's workforce plan expected later this year, these must support a more ambitious approach to advancing the clinical role of pharmacists across the NHS to better meet changing patient demand, backed by investment in pharmacy education and training.

Community pharmacists are readily accessible healthcare providers and medicine experts in the community setting and their counsel is often sought by patients and consumers on a number of subjects including the use of dietary supplements. Their role in the sale of and advice regarding natural health and drug alternatives has never been more relevant. The recent National Health Service (NHS) Interim People Plan calls for the NHS to put all staff front and centre of the way it operates and identifies pharmacists as a critical part of multidisciplinary teams, providing care across a wide range of increasingly complex patient needs. Despite existing demand to counsel patients on a vast range of medicines, more and more consumers are looking to their pharmacist to support and enhance their knowledge regarding the relevance of a growing range of supplementary nutrients now available. Nutritional supplementation is increasingly becoming the consumer's first choice for 'drug free' treatment or natural prevention that provides a true sense of taking control, which the prescription process often denies them. Historically the immense benefits provided by the NHS have instilled a general abdication of our personal health control, leaving us to rely on the health service to treat and cure as necessary. As our NHS has become visibly over-stretched we begin to realise what the rest of the world has known for centuries - good health is based primarily upon nutritional robustness. It may be stating the obvious but there is an excellent source of incremental revenue for the pharmacist who is willing to provide space to and advice for nutritional supplements.

A £5m project has been launched to introduce new blood tests in the National Health Service (NHS) that can diagnose Alzheimer's disease. The blood tests could be available on the NHS within five years and they can diagnose the disease earlier and more accurately than current methods, experts have said. Alzheimer's Research UK, the Alzheimer's Society and the National Institute of Health and Care Research have jointly launched the project. Susan Kohlhaas, Executive Director of Research and Partnerships at Alzheimer's Research UK, said that the NHS doesn't possess the "required levels of diagnostic infrastructure" to cope with the "growing demand" for dementia diagnosis. "Low-cost tools like blood tests that are non-invasive and simpler to administer than current gold standard methods are the answer to this," she added.

Louth and Horncastle's MP Victoria Atkins has taken the new role of Health Secretary today (13 November) amid the PM's cabinet reshuffle. Steve Barclay, the former Secretary of State for Health and Social Care was moved to become Environment Secretary after being assigned the role of Health Secretary. The following decision was made consequent to Steve Barclay being reassigned from the role. The news comes at a time when the NHS faces enduring challenges and industrial action, making this change particularly significant. MP Atkins is married to Paul Kenward, managing director of British Sugar, which also grows medicinal cannabis.

The Department of Health and Social Care (DHSC) has created a new NIHR Research Delivery Network (RDN) to support the successful delivery of health and social care research in England. The network, which will start operating from next year, will play a critical and active role in implementing government policies. It will support in implementing the Life Sciences Vision, the Future of UK Clinical Research Delivery vision, and policy for life sciences research and development. The new network would be mainly working on growing the amount of commercial clinical research as its key strategic ambition. Also, NIHR RDN will be responding to the findings of the Lord O'Shaughnessy review, which set out a clear blueprint for how the UK can return to its global leadership role.

Diabetes affects over 537 million people worldwide; by 2045, this is estimated to increase to 783 million. [1] With the growing prevalence of diabetes, it's even more important to utilise all options to support people with diabetes (PwDs) in managing their daily life with diabetes. Where do PwDs most often access healthcare support? On average, PwDs visit the pharmacy three-to-eight times more than the general population to obtain medicines and testing supplies.[2] It is clear that pharmacists play an integral role in empowering the self-management needs of PwDs beyond the traditional role of supplying medicines. This relationship, however, may be underutilised. Research suggests there is a lack of broad recognition of pharmacists as a key source of diabetes care, and that resource constraints - particularly following the COVID-19 pandemic - can interfere with patient education provision and training.[3,4] Furthermore, the circumstances and role of the pharmacy vary, nationally and internationally. At Roche Diabetes Care we would like to shine a light on the increasing value of community pharmacists as important figures in the well-being of PwDs.

The International Pharmaceutical Federation (FIP) launched a report on pharmacy-led common ailment schemes. The data was collected from 24 countries, including case studies from nine countries. It highlighted the growing demand for care models for ageing populations and the increase in chronic non-communicable diseases. Pharmacists had been managing the stress, including prescribing authority and provision of medicinal treatments. Paul Sinclair AM, Global President of FIP, said, "I believe this report is both a foundation and a catalyst - a foundation on which FIP and our member organizations could base initial strategies and a catalyst to drive us to seek even more diverse and comprehensive insights in the future.

Royal Pharmaceutical Society (RPS) Scotland has submitted its evidence to the Health, Social Care and Sport Committee's inquiry into 'Healthcare in remote and rural areas.' The Committee had sought views on what policies and actions would be most effective in addressing the issues people face when accessing healthcare in these areas. During the evidence session today (19 December), Laura Wilson, Director for RPS Scotland, highlighted the challenges faced by pharmacists and pharmacy in remote and rural areas, as well as provided some of the solutions for ensuring a sustainable pharmacy workforce. At present, people living in remote and rural areas of Scotland are required to travel to Glasgow or Aberdeen to undertake pharmacy training. Laura underscored the need to develop alternative education and training pathways, such as "grow your own" models, to support remote and rural areas to develop and retain local pharmacists.

Royal Pharmaceutical Society in England and the Royal College of General Practitioners have published recommendations for the roll-out and success of the GP Community Pharmacist Consultation Service (GP CPCS). These recommendations follow a workshop with stakeholders from pharmacy, general practice and representative bodies, examining ways to maximise the potential of the service and meet growing demand on the health service. The workshop report made five recommendations: The NHS England and Improvement should provide additional investment in local system support and resources to drive the CPCS implementation and uptake between general practice and community pharmacy. National representative bodies should work with NHS E&I to develop national and local engagement and streamline communication plans for CPCS referral pathway. Focus on expanding the role of community pharmacists in the management of minor illness. Evaluation of CPCS service and its impacts on general practice workload, patient outcomes and health inequalities.

NICE has recommended use of tucatinib as an option to treat HER2-positive breast cancer that has spread in people who have already tried 2 or more anti-HER2 treatments. The move is set to benefit around 400 people with advanced breast cancer. Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading. The medicine is taken as two 150 mg tablets twice daily along with anti-cancer medicines trastuzumab and capecitabine. Helen Knight, programme director in the NICE Centre for Health Technology Evaluation, said: "Unfortunately there is no cure for breast cancer that has spread to other parts of the body. There is also a lack of additional anti‑HER2 treatments which can postpone the need for chemotherapy, especially for people whose cancer has spread to their brain because their treatment options are even more limited.

McKesson UK's CEO Toby Anderson has stepped down from the role with immediate effect after over three years with the company. Toby joined McKesson UK as CEO in September 2018 moving from health & beauty retailer A.S. Watson Group, where he spent 12 years in various roles. As CEO Asia and Eastern Europe, Toby was responsible for a rapidly growing business with more than 3,300 stores - including 1,500 pharmacies. Prior to that Toby spent 11 years in a number of senior roles with J. Sainsbury, the second largest grocery retailer in the UK, his last role being Head of Online. Dominik Meüser from AURELIUS Group said: "We are extremely grateful for the commitment Toby has demonstrated over the years to help us achieve the McKesson vision of becoming the UK's leading healthcare organisation. His leadership, during a period of great uncertainty, has given us the solid foundations we can now build on to deliver sustained success in the future.

Kelso Pharma, the growing UK based specialty pharma business, has announced its first product launch with the release to the UK prescription medicines market of Acepiro (Acetylcysteine) 600mg effervescent tablets. Acepiro 600 mg effervescent tablets are indicated in adults only and are being made available to hospital and community prescribers in 20 and 30 day packs, with the 30 day pack consistent with monthly prescribing. The NHS List Price for the 30 day pack is £4.40, with the 20 day pack priced at £3.65. Acepiro is being launched by Stirling Anglian Pharmaceuticals (SAP), which was acquired by Kelso Pharma one year ago, providing a new UK platform and springboard for future sales growth for the business. The new product complements SAP's existing portfolio of three medicines: CosmoCol (macrogol 3350 plus electrolytes) powder for oral solution - an osmotic laxative indicated for the treatment of chronic constipation and faecal impaction. Stirlescent (naproxen) 250mg effervescent tablets - containing naproxen, which is a non-steroidal anti-inflammatory drug (NSAID).

Pharmacy leaders have called for reassurance that the workforce plan, expected by April 2023, will cover the entirety of the pharmacy workforce across the health service, including in community pharmacies. A joint letter has been signed by representatives from 14 pharmacy organisations which highlights that with continued pressures on services, it is more important than ever to support the pharmacy workforce so that the staff needed to deliver patient care now and into the future can be recruited, trained and retained. Mark Koziol, Pharmacists' Defence Association (PDA) Chairman said: "Our pharmacist members practise across the entire health system and have the potential to do far more to help patients and improve public health, but they can only do so safely if they are in appropriately staffed workplaces. This is a workforce issue, so it is important that the Government works with representatives of the pharmacist workforce, and of their employers, to get a suitably agreed plan in place." Thorrun Govind, English Pharmacy Board Chair, Royal Pharmaceutical Society (RPS), said: "It will be crucial to use the skills of all our health professions to support the NHS recovery, reduce health inequalities, manage the growing cost of long-term conditions, and deliver best value from medicines.

The Parliamentarians have called the government to urgently consider the short-term funding to stabilise the community pharmacy sector. 39 MPs and Peers from across the political spectrum have signed letters to the Health Secretary, Steve Barclay MP and raised their growing concern about the pressures facing England's community pharmacies and the risks this poses to patient care and safety. "Steve Barclay MP received correspondence from 23 Opposition MPs, with six Peers also signing a letter. Separately, 9 Conservative MPs also wrote to the Health Secretary and up to 10 others have signalled their intention to write to the relevant Minister," said the Pharmaceutical Services Negotiating Committee (PSNC). The Parliamentarians acknowledged that pharmacies have the potential to do more to support the NHS and they called for the government to urgently consider a commitment to working with the sector to create a fair and fit for purpose future funding model that ensures sustainability and properly funds pharmacies for what they do. All signatories also called for the introduction of a fairly-funded Pharmacy First service.

Titan PMR, a pioneer of cutting pharmacy technology has set up additional new team of 12 staff to cater for a deluge of independent pharmacists investing in new businesses. The company is utilising the opportunity that is underway as large chains look to sell off or close their community pharmacies, offering an opportunity for pharmacists looking to provide efficient dispensing and additional services. In January this year Lloyds Pharmacy, which was bought by a private equity firm in 2022, announced plans to close all its 237 branches inside Sainsbury's stores over the course of 2023. Currently, more than 5,500 of around 14,000 registered pharmacy premises across the UK are owned by corporates and supermarkets. Titan PMR - an innovative, cloud-based system which manages end-to-end pharmacy workflow - has become the preferred software platform especially amongst first time buyers who are keen to offer new services to patients. The new team at the Bristol-based company, hired to support this sector, sees its total workforce growing to more than 50 staff.

Developing a new medical drug is no small feat. It requires extensive research, knowledge, expertise in the field, rigorous testing and iteration of prototypes, and strong organizational skills to manage these tasks. It is important to use the right tools to make this process as efficient and successful as possible. With the right tools available, you can streamline development, manage resources and personnel more effectively, and maximize the chances of success. Here are some tools that might be useful when developing a new medical drug: ANALYTICAL TESTING TOOLS One of the best tools available to medical drug developers is analytical testing tools. These allow you to quickly and accurately test various components of the new medication, ensuring that it meets all safety requirements and is ready for clinical trials. As highlighted by the team behind Venogen, various methods of analyzing, chemical identification, and purity certification can be used to ensure product quality. Be sure to select a tool that can accurately analyze the specific components of your new drug. When finding analytical testing tools for your drug development process, it is important to consider the tool's scalability. Consider the size and scope of your project and select a tool that can grow with you. You can also work with experts to find the right analytical testing tools for your development needs.

The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the NHS ad campaign highlighting how community pharmacies can support patients with non-health advice amidst the growing pressure on pharmacies. It believes the campaign will only 'worsen' the pressure on pharmacies. "It is always deeply concerning to see campaigns directing people to pharmacies without any regard for the pressures they are under: it is irresponsible and extremely unhelpful," said PSNC Chief Executive Janet Morrison. She called the campaign 'particularly irritating' just weeks after the committee rejected a series of proposals from NHS England and DHSC on relief measures to ease pressure on pharmacies as being totally inadequate. "NHS England Board Members have noted the pressure on pharmacies - so why are their teams so often acting to make these pressures worse? We need to see a radical change in how NHS England treats pharmacies and we're continuing to press for that via our influencing and campaigning work," she added. The NHS launched the new campaign on Monday (27 February) to highlight how high-street pharmacies can support patients with non-urgent health advice for minor conditions including coughs, aches and colds.

It's 2022 and data is everything, isn't it? Advertising, decision-making, you name it, data is behind it. What if an ePharmacy could use its own data as an asset? If you knew that sooner or later, you'll be able to turn your data into a revenue stream, wouldn't that be something? And this is exactly what Convert Group does. Convert Group offers the complete eCommerce SaaS ecosystem that helps ePharmacists and brands grow sales, streamline collaboration, and seize data monetization opportunities. Built for scale, Convert Group's platform leverages automation and offers a unique user experience backed by our leading eCommerce team.

Growing patients stricken by problems, defects, and illnesses of the vision are truly choosing to travel overseas foreign places for low cost eye surgery India.

Have you ever wondered about the health benefits of ginseng? It's been used for thousands of years by people in Asia and Eastern Europe, but did you know it's good for more than just boosting energy? The ginseng plant deals with 11 combinations of short, slowly growing plants with fleshy roots. It can revive and improve well-being. This article will explore how this herbal plant can benefit your body. 11 Health Benefits of the Ginseng Plant There are two types of ginseng plants mainly: Asian or Korean ginseng (Panax ginseng) American ginseng (Panax quinquefolius). Studies have discovered that the distinct types have various uses. American ginseng is believed to be less stimulating in traditional Chinese medicine than the Asian one. There are several other herbs known as ginseng, like eleuthero or Siberian ginseng, but they don't have the valuable content of ginsenosides. Ginseng has traditionally been used for several medical illnesses. However, its benefits for most of them have yet to be thoughtfully researched. These include: 1/11_It may help your lungs work better. ginseng plant lowers lungs infections.Ginseng may also help your lungs, according to a published study in the Journal of Ethnopharmacology. Researchers found that one of the active ingredients in ginseng, ginsenoside Rg1 has an anti-inflammatory effect on the lungs and can even protect against asthma and bronchitis. They found that rats with asthma had less inflammation after being given doses of ginseng for two weeks compared to rats not given any. They also observed that rats with pneumonia had fewer symptoms when they were treated with inhaled doses of ginsenoside Rg1 or orally administered doses of Korean red ginseng extract (KRGE). 2/11_It may lower blood sugar levels. ginseng plant lower blood sugar levels. It's not just your imagination-ginseng can help lower blood sugar levels in people with diabetes. It also has been proven to reduce the amount of cholesterol in your body. It